Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Teva Pharmaceutical Industries Limited (TEVA)

7.95   0.12 (1.53%) 06-29 17:41
Open: 7.885 Pre. Close: 7.83
High: 7.98 Low: 7.781
Volume: 9,649,789 Market Cap: 9,063(M)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.99 - 8.02 8.02 - 8.05
Low: 7.69 - 7.73 7.73 - 7.77
Close: 7.88 - 7.95 7.95 - 8

Technical analysis

as of: 2022-06-29 4:57:58 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 10.21     One year: 11.11
Support: Support1: 7.48    Support2: 6.23
Resistance: Resistance1: 8.74    Resistance2: 9.52
Pivot: 7.89
Moving Average: MA(5): 7.88     MA(20): 8.2
MA(100): 8.5     MA(250): 8.85
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 34.9     %D(3): 28.4
RSI: RSI(14): 45.2
52-week: High: 10.5  Low: 7.23
Average Vol(K): 3-Month: 9,891 (K)  10-Days: 15,519 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TEVA ] has closed below upper band by 44.5%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 29 Jun 2022
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022 - Yahoo Finance

Wed, 29 Jun 2022
Neurim Loses 2nd Bid To Stop Sale Of Rival Drug Brand - Law360

Wed, 29 Jun 2022
Teva Pharmaceutical Industries Ltd (TEVA) Stock: Do Analysts Think You Should Sell? - InvestorsObserver

Wed, 29 Jun 2022
With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug - Endpoints News

Tue, 28 Jun 2022
2 Buffett Stocks That Outperformed the S&P During the Great Recession - The Motley Fool

Sat, 25 Jun 2022
New & Notable: Latest releases from Reebok and Teva - NBC News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 1,100 (M)
Shares Float 1,100 (M)
% Held by Insiders 1.5 (%)
% Held by Institutions 46 (%)
Shares Short 16,890 (K)
Shares Short P.Month 20,910 (K)

Stock Financials

EPS 0.66
EPS Est Next Qtl 1.09
EPS Est This Year 4.23
EPS Est Next Year 3.69
Book Value (p.s.) 9.48
Profit Margin (%) 2.6
Operating Margin (%) 19.3
Return on Assets (ttm) 3.9
Return on Equity (ttm) 4
Qtrly Rev. Growth -8
Gross Profit (p.s.) 6.9
Sales Per Share 14.43
EBITDA (p.s.) 4
Qtrly Earnings Growth 0
Operating Cash Flow 798 (M)
Levered Free Cash Flow 2,310 (M)

Stock Valuations

PE Ratio 12.04
PEG Ratio 0.8
Price to Book value 0.83
Price to Sales 0.55
Price to Cash Flow 10.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-12-11
Ex-Dividend Date 2017-11-26
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.